{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T06:44:29Z","timestamp":1794206669694,"version":"4.8.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rheumatoid arthritis (RA) is a chronic, autoimmune disorder characterized by joint inflammation and pain. In patients with RA, metabolomic approaches, i.e., high-throughput profiling of small-molecule metabolites, on plasma or serum has thus far enabled the discovery of biomarkers for clinical subgroups, risk factors, and predictors of treatment response. Despite these recent advancements, the identification of blood metabolites that reflect quantitative disease activity remains an important challenge in precision medicine for RA. Herein, we use global plasma metabolomic profiling analyses to detect metabolites associated with, and predictive of, quantitative disease activity in patients with RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS\/MS) was performed on a discovery cohort consisting of 128 plasma samples from 64 RA patients and on a validation cohort of 12 samples from 12 patients. The resulting metabolomic profiles were analyzed with two different strategies to find metabolites associated with RA disease activity defined by the Disease Activity Score-28 using C-reactive protein (DAS28-CRP). More specifically, mixed-effects regression models were used to identify metabolites differentially abundant between two disease activity groups (\u201clower\u201d, DAS28-CRP \u2264 3.2; and \u201chigher\u201d, DAS28-CRP &gt; 3.2) and to identify metabolites significantly associated with DAS28-CRP scores. A generalized linear model (GLM) was then constructed for estimating DAS28-CRP using plasma metabolite abundances. Finally, for associating metabolites with CRP (an indicator of inflammation), metabolites differentially abundant between two patient groups (\u201clow-CRP\u201d, CRP \u2264 3.0\u2009mg\/L; \u201chigh-CRP\u201d, CRP &gt; 3.0\u2009mg\/L) were investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified 33 metabolites differentially abundant between the lower and higher disease activity groups (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05). Additionally, we identified 51 metabolites associated with DAS28-CRP (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05). A GLM based upon these 51 metabolites resulted in higher prediction accuracy (mean absolute error [MAE] \u00b1 SD: 1.51 \u00b1 1.77) compared to a GLM without feature selection (MAE \u00b1 SD: 2.02 \u00b1 2.21). The predictive value of this feature set was further demonstrated on a validation cohort of twelve plasma samples, wherein we observed a stronger correlation between predicted and actual DAS28-CRP (with feature selection: Spearman\u2019s\n                      <jats:italic>\u03c1<\/jats:italic>\n                      = 0.69, 95% CI: [0.18, 0.90]; without feature selection: Spearman\u2019s\n                      <jats:italic>\u03c1<\/jats:italic>\n                      = 0.18, 95% CI: [\u22120.44, 0.68]). Lastly, among all identified metabolites, the abundances of eight were significantly associated with the CRP patient groups while controlling for potential confounders (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We demonstrate for the first time the prediction of quantitative disease activity in RA using plasma metabolomes. The metabolites identified herein provide insight into circulating pro-\/anti-inflammatory metabolic signatures that reflect disease activity and inflammatory status in RA patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-021-02537-4","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T01:12:19Z","timestamp":1623114739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Plasma metabolomic profiling in patients with rheumatoid arthritis identifies biochemical features predictive of quantitative disease activity"],"prefix":"10.1186","volume":"23","author":[{"given":"Benjamin","family":"Hur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry A.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Warrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Taneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"John M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3005-2798","authenticated-orcid":false,"given":"Jaeyun","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"issue":"1","key":"2537_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41413-017-0004-5","volume":"6","author":"Q Guo","year":"2018","unstructured":"Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6(1):1\u201314.","journal-title":"Bone Res"},{"issue":"9","key":"2537_CR2","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 Rheumatoid Arthritis Classification Criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569\u201381. https:\/\/doi.org\/10.1002\/art.27584.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2537_CR3","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4(1):18001. https:\/\/doi.org\/10.1038\/nrdp.2018.1.","journal-title":"Nat Rev Dis Primers"},{"issue":"6937","key":"2537_CR4","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature01661","volume":"423","author":"GS Firestein","year":"2003","unstructured":"Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937):356\u201361. https:\/\/doi.org\/10.1038\/nature01661.","journal-title":"Nature"},{"issue":"13","key":"2537_CR5","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360\u201372. https:\/\/doi.org\/10.1001\/jama.2018.13103.","journal-title":"JAMA"},{"issue":"1","key":"2537_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B","volume":"43","author":"AJ MacGregor","year":"2000","unstructured":"MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 2000;43(1):30\u20137. https:\/\/doi.org\/10.1002\/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2537_CR7","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/art.30155","volume":"63","author":"CS Crowson","year":"2011","unstructured":"Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(3):633\u20139. https:\/\/doi.org\/10.1002\/art.30155.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2537_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.yfrne.2014.04.004","volume":"35","author":"ST Ngo","year":"2014","unstructured":"Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. 2014;35(3):347\u201369. https:\/\/doi.org\/10.1016\/j.yfrne.2014.04.004.","journal-title":"Front Neuroendocrinol"},{"issue":"01","key":"2537_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/ard.2008.096487","volume":"69","author":"D Sugiyama","year":"2010","unstructured":"Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2010;69(01):70\u201381. https:\/\/doi.org\/10.1136\/ard.2008.096487.","journal-title":"Ann Rheum Dis"},{"key":"2537_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fnut.2017.00052","volume":"4","author":"S Khanna","year":"2017","unstructured":"Khanna S, Jaiswal KS, Gupta B. Managing rheumatoid arthritis with dietary interventions. Fron Nutr. 2017;4:52. https:\/\/doi.org\/10.3389\/fnut.2017.00052.","journal-title":"Fron Nutr"},{"issue":"4","key":"2537_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2217\/ijr.14.25","volume":"9","author":"A Juli\u00e0","year":"2014","unstructured":"Juli\u00e0 A, Alonso A, Marsal S. Metabolomics in rheumatic diseases. Int J Clin Rheumatol. 2014;9(4):353\u201369. https:\/\/doi.org\/10.2217\/ijr.14.25.","journal-title":"Int J Clin Rheumatol"},{"issue":"12","key":"2537_CR12","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/rheumatology\/41.12.1367","volume":"41","author":"D Aletaha","year":"2002","unstructured":"Aletaha D, Smolen J. The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheumatology. 2002;41(12):1367\u201374. https:\/\/doi.org\/10.1093\/rheumatology\/41.12.1367.","journal-title":"Rheumatology"},{"issue":"10","key":"2537_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3390\/cells7100161","volume":"7","author":"H-Y Yap","year":"2018","unstructured":"Yap H-Y, Tee SZ-Y, Wong MM-T, Chow S-K, Peh S-C, Teow S-Y. Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development. Cells. 2018;7(10):161. https:\/\/doi.org\/10.3390\/cells7100161.","journal-title":"Cells"},{"issue":"6","key":"2537_CR14","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1136\/ard.2004.029751","volume":"64","author":"JJ Haringman","year":"2005","unstructured":"Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64(6):834\u20138. https:\/\/doi.org\/10.1136\/ard.2004.029751.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2537_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3349\/ymj.2011.52.1.113","volume":"52","author":"S-J Chung","year":"2011","unstructured":"Chung S-J, Kwon Y-J, Park M-C, Park Y-B, Lee S-K. The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients. Yonsei Med J. 2011;52(1):113\u201320. https:\/\/doi.org\/10.3349\/ymj.2011.52.1.113.","journal-title":"Yonsei Med J"},{"issue":"10","key":"2537_CR16","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/annrheumdis-2016-210997","volume":"76","author":"EE Arts","year":"2017","unstructured":"Arts EE, Fransen J, Den Broeder AA, van Riel PL, Popa CD. Low disease activity (DAS28\u22643.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study. Ann Rheum Dis. 2017;76(10):1693\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210997.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2537_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"A Van Gestel","year":"1996","unstructured":"Van Gestel A, Prevoo M, Van\u2019t Hof M, Van Rijswijk M, Van de Putte L, Van Riel P. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism criteria. Arthritis Rheum. 1996;39(1):34\u201340.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2537_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"M Prevoo","year":"1995","unstructured":"Prevoo M, Van\u2019T Hof MA, Kuper H, Van Leeuwen M, Van De Putte L, Van Riel P. Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44\u20138. https:\/\/doi.org\/10.1002\/art.1780380107.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2537_CR19","first-page":"S93","volume":"23","author":"J Fransen","year":"2005","unstructured":"Fransen J, Van Riel P. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23(5):S93.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"2537_CR20","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acr.21649","volume":"64","author":"J Anderson","year":"2012","unstructured":"Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res. 2012;64(5):640\u20137. https:\/\/doi.org\/10.1002\/acr.21649.","journal-title":"Arthritis Care Res"},{"issue":"6","key":"2537_CR21","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s10067-018-4021-6","volume":"37","author":"J Li","year":"2018","unstructured":"Li J, Che N, Xu L, Zhang Q, Wang Q, Tan W, et al. LC-MS-based serum metabolomics reveals a distinctive signature in patients with rheumatoid arthritis. Clin Rheumatol. 2018;37(6):1493\u2013502. https:\/\/doi.org\/10.1007\/s10067-018-4021-6.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"2537_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nrm3314","volume":"13","author":"GJ Patti","year":"2012","unstructured":"Patti GJ, Yanes O, Siuzdak G. Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol. 2012;13(4):263\u20139. https:\/\/doi.org\/10.1038\/nrm3314.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2537_CR23","doi-asserted-by":"publisher","first-page":"a000588","DOI":"10.1101\/mcs.a000588","volume":"1","author":"CB Clish","year":"2015","unstructured":"Clish CB. Metabolomics: an emerging but powerful tool for precision medicine. Mol Case Stud. 2015;1(1):a000588. https:\/\/doi.org\/10.1101\/mcs.a000588.","journal-title":"Mol Case Stud"},{"issue":"1","key":"2537_CR24","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13075-018-1729-2","volume":"20","author":"XM Teitsma","year":"2018","unstructured":"Teitsma XM, Yang W, Jacobs JW, Peth\u00f6-Schramm A, Borm ME, Harms AC, et al. Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology. Arthritis Res Ther. 2018;20(1):230. https:\/\/doi.org\/10.1186\/s13075-018-1729-2.","journal-title":"Arthritis Res Ther"},{"key":"2537_CR25","doi-asserted-by":"publisher","unstructured":"Sasaki C, Hiraishi T, Oku T, Okuma K, Suzumura K, Hashimoto M, Ito H, Aramori I, Hirayama Y. Metabolomic approach to the exploration of biomarkers associated with disease activity in rheumatoid arthritis. Plos One 2019;14(7):e0219400. https:\/\/doi.org\/10.1371\/journal.pone.0219400.","DOI":"10.1371\/journal.pone.0219400"},{"issue":"6","key":"2537_CR26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3899\/jrheum.180537","volume":"46","author":"K Hambardzumyan","year":"2019","unstructured":"Hambardzumyan K, Bolce RJ, Wallman JK, Van Vollenhoven RF, Saevarsdottir S. Serum biomarkers for prediction of response to methotrexate monotherapy in early rheumatoid arthritis: results from the SWEFOT trial. J Rheumatol. 2019;46(6):555\u201363. https:\/\/doi.org\/10.3899\/jrheum.180537.","journal-title":"J Rheumatol"},{"issue":"1","key":"2537_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-05044-4","volume":"9","author":"S Tasaki","year":"2018","unstructured":"Tasaki S, Suzuki K, Kassai Y, Takeshita M, Murota A, Kondo Y, et al. Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission. Nat Commun. 2018;9(1):1\u201312.","journal-title":"Nat Commun"},{"issue":"6","key":"2537_CR28","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/art.37921","volume":"65","author":"SR Kapoor","year":"2013","unstructured":"Kapoor SR, Filer A, Fitzpatrick MA, Fisher BA, Taylor PC, Buckley CD, et al. Metabolic profiling predicts response to anti\u2013tumor necrosis factor \u03b1 therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2013;65(6):1448\u201356. https:\/\/doi.org\/10.1002\/art.37921.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2537_CR29","doi-asserted-by":"publisher","first-page":"e0163087","DOI":"10.1371\/journal.pone.0163087","volume":"11","author":"BV Cuppen","year":"2016","unstructured":"Cuppen BV, Fu J, Van Wietmarschen HA, Harms AC, Koval S, Marijnissen AC, et al. Exploring the inflammatory metabolomic profile to predict response to TNF-\u03b1 inhibitors in rheumatoid arthritis. Plos One. 2016;11(9):e0163087. https:\/\/doi.org\/10.1371\/journal.pone.0163087.","journal-title":"Plos One"},{"issue":"6","key":"2537_CR30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3390\/metabo10060243","volume":"10","author":"UW Liebal","year":"2020","unstructured":"Liebal UW, Phan AN, Sudhakar M, Raman K, Blank LM. Machine learning applications for mass spectrometry-based metabolomics. Metabolites. 2020;10(6):243. https:\/\/doi.org\/10.3390\/metabo10060243.","journal-title":"Metabolites"},{"key":"2537_CR31","first-page":"14","volume":"69","author":"PM Welsing","year":"2004","unstructured":"Welsing PM, van Riel PL. The Nijmegen inception cohort of early rheumatoid arthritis. J Rheumatol Suppl. 2004;69:14\u201321.","journal-title":"J Rheumatol Suppl"},{"key":"2537_CR32","volume-title":"Fitting linear mixed-effects models using lme4","author":"D Bates","year":"2014","unstructured":"Bates D, M\u00e4chler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. arXiv preprint arXiv:14065823 2014."},{"issue":"1","key":"2537_CR33","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/1471-2474-15-368","volume":"15","author":"L Siemons","year":"2014","unstructured":"Siemons L, ten Klooster PM, Vonkeman HE, van Riel PL, Glas CA, van de Laar MA. How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis. BMC Musculoskel Disord. 2014;15(1):368. https:\/\/doi.org\/10.1186\/1471-2474-15-368.","journal-title":"BMC Musculoskel Disord"},{"issue":"8","key":"2537_CR34","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1136\/ard.2007.079913","volume":"67","author":"B Radovits","year":"2008","unstructured":"Radovits B, Fransen J, Van Riel P, Laan R. Influence of age and gender on the 28-joint Disease Activity Score (DAS28) in rheumatoid arthritis. Ann Rheum Dis. 2008;67(8):1127\u201331. https:\/\/doi.org\/10.1136\/ard.2007.079913.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2537_CR35","first-page":"1040","volume":"32","author":"VK Ranganath","year":"2005","unstructured":"Ranganath VK, Elashoff DA, Khanna D, Park G, Peter JB, Paulus HE. Age adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patients. J Rheumatol. 2005;32(6):1040\u20132.","journal-title":"J Rheumatol"},{"key":"2537_CR36","unstructured":"Kuznetsova A, Brockhoff PB, Christensen RHB. Package \u2018lmertest\u2019. https:\/\/cran.r-project.org\/web\/packages\/lmerTest."},{"key":"2537_CR37","doi-asserted-by":"publisher","unstructured":"Yang XY, Di Zheng K, Lin K, Zheng G, Zou H, Wang JM, Lin YY, Chuka CM, Ge RS, Zhai W. Energy metabolism disorder as a contributing factor of rheumatoid arthritis: a comparative proteomic and metabolomic study. Plos One 2015;10(7):e0132695. https:\/\/doi.org\/10.1371\/journal.pone.0132695.","DOI":"10.1371\/journal.pone.0132695"},{"issue":"21","key":"2537_CR38","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.2174\/092986712801323171","volume":"19","author":"J Zhou","year":"2012","unstructured":"Zhou J, Chan L, Zhou S. Trigonelline: a plant alkaloid with therapeutic potential for diabetes and central nervous system disease. Curr Med Chem. 2012;19(21):3523\u201331. https:\/\/doi.org\/10.2174\/092986712801323171.","journal-title":"Curr Med Chem"},{"issue":"5-6","key":"2537_CR39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000479088","volume":"100","author":"J-Y Zhou","year":"2017","unstructured":"Zhou J-Y, Du X-H, Zhang Z, Qian G-S. Trigonelline inhibits inflammation and protects \u03b2 cells to prevent fetal growth restriction during pregnancy in a mouse model of diabetes. Pharmacology. 2017;100(5-6):209\u201317. https:\/\/doi.org\/10.1159\/000479088.","journal-title":"Pharmacology"},{"key":"2537_CR40","doi-asserted-by":"publisher","unstructured":"Foresti R, Green CJ, Motterlini R. Generation of bile pigments by haem oxygenase: a refined cellular strategy in response to stressful insults. Biochemical Society Symposia. 2004;71:177\u2013192.\u00a0https:\/\/doi.org\/10.1042\/bss0710177.","DOI":"10.1042\/bss0710177"},{"issue":"3","key":"2537_CR41","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.exer.2008.06.007","volume":"87","author":"L Bellner","year":"2008","unstructured":"Bellner L, Vitto M, Patil KA, Dunn MW, Regan R, Laniado-Schwartzman M. Exacerbated corneal inflammation and neovascularization in the HO-2 null mice is ameliorated by biliverdin. Exp Eye Res. 2008;87(3):268\u201378. https:\/\/doi.org\/10.1016\/j.exer.2008.06.007.","journal-title":"Exp Eye Res"},{"issue":"2","key":"2537_CR42","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1053\/j.gastro.2004.05.059","volume":"127","author":"A Nakao","year":"2004","unstructured":"Nakao A, Otterbein LE, Overhaus M, Sarady JK, Tsung A, Kimizuka K, et al. Biliverdin protects the functional integrity of a transplanted syngeneic small bowel. Gastroenterology. 2004;127(2):595\u2013606. https:\/\/doi.org\/10.1053\/j.gastro.2004.05.059.","journal-title":"Gastroenterology"},{"issue":"6","key":"2537_CR43","doi-asserted-by":"publisher","first-page":"L1131","DOI":"10.1152\/ajplung.00458.2004","volume":"289","author":"JK Sarady-Andrews","year":"2005","unstructured":"Sarady-Andrews JK, Liu F, Gallo D, Nakao A, Overhaus M, Ollinger R, et al. Biliverdin administration protects against endotoxin-induced acute lung injury in rats. Am J Physio Lung Cell Mol Physiol. 2005;289(6):L1131\u20137.","journal-title":"Am J Physio Lung Cell Mol Physiol"},{"issue":"11","key":"2537_CR44","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1002\/ijc.22978","volume":"121","author":"PE Gibbs","year":"2007","unstructured":"Gibbs PE, Maines MD. Biliverdin inhibits activation of NF-\u03baB: reversal of inhibition by human biliverdin reductase. Int J Cancer. 2007;121(11):2567\u201374. https:\/\/doi.org\/10.1002\/ijc.22978.","journal-title":"Int J Cancer"},{"issue":"12","key":"2537_CR45","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1089\/ars.2007.1807","volume":"9","author":"R \u00d6llinger","year":"2007","unstructured":"\u00d6llinger R, Wang H, Yamashita K, Wegiel B, Thomas M, Margreiter R, et al. Therapeutic applications of bilirubin and biliverdin in transplantation. Antioxid Redox Signal. 2007;9(12):2175\u201386. https:\/\/doi.org\/10.1089\/ars.2007.1807.","journal-title":"Antioxid Redox Signal"},{"key":"2537_CR46","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cca.2017.04.006","volume":"469","author":"Y-F Peng","year":"2017","unstructured":"Peng Y-F, Wang J-L, Pan G-G. The correlation of serum bilirubin levels with disease activity in patients with rheumatoid arthritis. Clin Chim Acta. 2017;469:187\u201390. https:\/\/doi.org\/10.1016\/j.cca.2017.04.006.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"2537_CR47","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4021\/jocmr444w","volume":"2","author":"D Fischman","year":"2010","unstructured":"Fischman D, Valluri A, Gorrepati VS, Murphy ME, Peters I, Cheriyath P. Bilirubin as a protective factor for rheumatoid arthritis: an NHANES study of 2003-2006 data. J Clin Med Res. 2010;2(6):256\u201360. https:\/\/doi.org\/10.4021\/jocmr444w.","journal-title":"J Clin Med Res"},{"issue":"12","key":"2537_CR48","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1016\/j.biocel.2013.09.014","volume":"45","author":"S Jangi","year":"2013","unstructured":"Jangi S, Otterbein L, Robson S. The molecular basis for the immunomodulatory activities of unconjugated bilirubin. Int J Biochem Cell Biol. 2013;45(12):2843\u201351. https:\/\/doi.org\/10.1016\/j.biocel.2013.09.014.","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"2537_CR49","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nprot.2007.511","volume":"3","author":"DP Enot","year":"2008","unstructured":"Enot DP, Lin W, Beckmann M, Parker D, Overy DP, Draper J. Preprocessing, classification modeling and feature selection using flow injection electrospray mass spectrometry metabolite fingerprint data. Nat Protoc. 2008;3(3):446\u201370. https:\/\/doi.org\/10.1038\/nprot.2007.511.","journal-title":"Nat Protoc"},{"key":"2537_CR50","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fmolb.2016.00030","volume":"3","author":"D Grissa","year":"2016","unstructured":"Grissa D, P\u00e9t\u00e9ra M, Brandolini M, Napoli A, Comte B, Pujos-Guillot E. Feature selection methods for early predictive biomarker discovery using untargeted metabolomic data. Front Mol Biosci. 2016;3:30.","journal-title":"Front Mol Biosci"},{"issue":"9","key":"2537_CR51","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1136\/ard.2004.032151","volume":"64","author":"JV van Zanten","year":"2005","unstructured":"van Zanten JV, Ring C, Carroll D, Kitas GD. Increased C reactive protein in response to acute stress in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64(9):1299\u2013304. https:\/\/doi.org\/10.1136\/ard.2004.032151.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2537_CR52","doi-asserted-by":"publisher","first-page":"e6242","DOI":"10.1371\/journal.pone.0006242","volume":"4","author":"J Graf","year":"2009","unstructured":"Graf J, Scherzer R, Grunfeld C, Imboden J. Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. Plos One. 2009;4(7):e6242. https:\/\/doi.org\/10.1371\/journal.pone.0006242.","journal-title":"Plos One"},{"issue":"8","key":"2537_CR53","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1002\/art.38021","volume":"65","author":"SP Young","year":"2013","unstructured":"Young SP, Kapoor SR, Viant MR, Byrne JJ, Filer A, Buckley CD, et al. The impact of inflammation on metabolomic profiles in patients with arthritis. Arthritis Rheum. 2013;65(8):2015\u201323. https:\/\/doi.org\/10.1002\/art.38021.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2537_CR54","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"G Wells","year":"2009","unstructured":"Wells G, Becker J, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68(6):954\u201360. https:\/\/doi.org\/10.1136\/ard.2007.084459.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2537_CR55","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41573-019-0032-5","volume":"18","author":"CH Patel","year":"2019","unstructured":"Patel CH, Leone RD, Horton MR, Powell JD. Targeting metabolism to regulate immune responses in autoimmunity and cancer. Nat Rev Drug Discov. 2019;18(9):669\u201388. https:\/\/doi.org\/10.1038\/s41573-019-0032-5.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2537_CR56","doi-asserted-by":"publisher","first-page":"999","DOI":"10.4049\/jimmunol.1601318","volume":"198","author":"IA Bettencourt","year":"2017","unstructured":"Bettencourt IA, Powell JD. Targeting metabolism as a novel therapeutic approach to autoimmunity, inflammation, and transplantation. J Immunol. 2017;198(3):999\u20131005. https:\/\/doi.org\/10.4049\/jimmunol.1601318.","journal-title":"J Immunol"},{"issue":"3","key":"2537_CR57","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/ar3885","volume":"14","author":"CM Spies","year":"2012","unstructured":"Spies CM, Straub RH, Buttgereit F. Energy metabolism and rheumatic diseases: from cell to organism. Arthritis Res Ther. 2012;14(3):216. https:\/\/doi.org\/10.1186\/ar3885.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2537_CR58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13075-015-0542-4","volume":"17","author":"Z Yang","year":"2015","unstructured":"Yang Z, Matteson EL, Goronzy JJ, Weyand CM. T-cell metabolism in autoimmune disease. Arthritis Res Ther. 2015;17(1):29. https:\/\/doi.org\/10.1186\/s13075-015-0542-4.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"2537_CR59","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/cei.13228","volume":"197","author":"U Fearon","year":"2019","unstructured":"Fearon U, Hanlon M, Wade S, Fletcher J. Altered metabolic pathways regulate synovial inflammation in rheumatoid arthritis. Clin Exp Immunol. 2019;197(2):170\u201380. https:\/\/doi.org\/10.1111\/cei.13228.","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"2537_CR60","doi-asserted-by":"publisher","first-page":"e1887","DOI":"10.1038\/cddis.2015.246","volume":"6","author":"M Chimenti","year":"2015","unstructured":"Chimenti M, Triggianese P, Conigliaro P, Candi E, Melino G, Perricone R. The interplay between inflammation and metabolism in rheumatoid arthritis. Cell Death Dis. 2015;6(9):e1887. https:\/\/doi.org\/10.1038\/cddis.2015.246.","journal-title":"Cell Death Dis"},{"issue":"5","key":"2537_CR61","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3390\/jcm8050753","volume":"8","author":"E Sanchez-Lopez","year":"2019","unstructured":"Sanchez-Lopez E, Cheng A, Guma M. Can metabolic pathways be therapeutic targets in rheumatoid arthritis? J Clin Med. 2019;8(5):753. https:\/\/doi.org\/10.3390\/jcm8050753.","journal-title":"J Clin Med"},{"issue":"8","key":"2537_CR62","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/biot.201100305","volume":"7","author":"J Sung","year":"2012","unstructured":"Sung J, Wang Y, Chandrasekaran S, Witten DM, Price ND. Molecular signatures from omics data: from chaos to consensus. Biotechnol J. 2012;7(8):946\u201357. https:\/\/doi.org\/10.1002\/biot.201100305.","journal-title":"Biotechnol J"},{"key":"2537_CR63","doi-asserted-by":"crossref","unstructured":"Coras R, D Murillo-Saich J, Guma M. Circulating pro-and anti-inflammatory metabolites and its potential role in rheumatoid arthritis pathogenesis. Cells 2020, 9(4):827.","DOI":"10.3390\/cells9040827"},{"key":"2537_CR64","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3389\/fphar.2012.00047","volume":"3","author":"B Wegiel","year":"2012","unstructured":"Wegiel B, Otterbein L. Go green: the anti-inflammatory effects of biliverdin reductase. Front Pharmacol. 2012;3:47.","journal-title":"Front Pharmacol"},{"issue":"46","key":"2537_CR65","doi-asserted-by":"publisher","first-page":"18849","DOI":"10.1073\/pnas.1108571108","volume":"108","author":"B Wegiel","year":"2011","unstructured":"Wegiel B, Gallo D, Csizmadia E, Roger T, Kaczmarek E, Harris C, et al. Biliverdin inhibits Toll-like receptor-4 (TLR4) expression through nitric oxide-dependent nuclear translocation of biliverdin reductase. Proc Natl Acad Sci. 2011;108(46):18849\u201354. https:\/\/doi.org\/10.1073\/pnas.1108571108.","journal-title":"Proc Natl Acad Sci"},{"key":"2537_CR66","unstructured":"Vogel ME, Zucker SD. Bilirubin acts as an endogenous regulator of inflammation by disrupting adhesion molecule-mediated leukocyte migration. Inflamm Cell Signal 2016;3(1):e1178."},{"issue":"3","key":"2537_CR67","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.4049\/jimmunol.181.3.1887","volume":"181","author":"Y Liu","year":"2008","unstructured":"Liu Y, Li P, Lu J, Xiong W, Oger J, Tetzlaff W, et al. Bilirubin possesses powerful immunomodulatory activity and suppresses experimental autoimmune encephalomyelitis. J Immunol. 2008;181(3):1887\u201397. https:\/\/doi.org\/10.4049\/jimmunol.181.3.1887.","journal-title":"J Immunol"},{"key":"2537_CR68","doi-asserted-by":"publisher","first-page":"825","DOI":"10.3389\/fphar.2019.00825","volume":"10","author":"W Tang","year":"2019","unstructured":"Tang W, Wu Y, Wu B. Heme catabolic pathway in inflammation and immune disorders. Front Pharmacol. 2019;10:825.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2537_CR69","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4161\/cc.6.1.3700","volume":"6","author":"R \u00d6llinger","year":"2007","unstructured":"\u00d6llinger R, Yamashita K, Bilban M, Erat A, Kogler P, Thomas M, et al. Bilirubin and biliverdin treatment of atherosclerotic diseases. Cell Cycle. 2007;6(1):39\u201343. https:\/\/doi.org\/10.4161\/cc.6.1.3700.","journal-title":"Cell Cycle"},{"issue":"21","key":"2537_CR70","doi-asserted-by":"publisher","first-page":"8569","DOI":"10.1074\/jbc.R116.767434","volume":"292","author":"SJ Pellock","year":"2017","unstructured":"Pellock SJ, Redinbo MR. Glucuronides in the gut: sugar-driven symbioses between microbe and host. J Biol Chem. 2017;292(21):8569\u201376. https:\/\/doi.org\/10.1074\/jbc.R116.767434.","journal-title":"J Biol Chem"},{"issue":"16","key":"2537_CR71","first-page":"3752","volume":"56","author":"K Takasuna","year":"1996","unstructured":"Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, et al. Involvement of \u03b2-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 1996;56(16):3752\u20137.","journal-title":"Cancer Res"},{"issue":"2","key":"2537_CR72","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1124\/jpet.111.191122","volume":"341","author":"A LoGuidice","year":"2012","unstructured":"LoGuidice A, Wallace BD, Bendel L, Redinbo MR, Boelsterli UA. Pharmacologic targeting of bacterial \u03b2-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice. J Pharmacol Exp Ther. 2012;341(2):447\u201354. https:\/\/doi.org\/10.1124\/jpet.111.191122.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2537_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-015-0257-9","volume":"8","author":"J Chen","year":"2016","unstructured":"Chen J, Wright K, Davis JM, Jeraldo P, Marietta EV, Murray J, et al. An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. Genome Med. 2016;8(1):1\u201314.","journal-title":"Genome Med"},{"issue":"1","key":"2537_CR74","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/1756-185X.13062","volume":"22","author":"M He","year":"2019","unstructured":"He M, Harms AC, van Wijk E, Wang M, Berger R, Koval S, et al. Role of amino acids in rheumatoid arthritis studied by metabolomics. Int J Rheum Dis. 2019;22(1):38\u201346. https:\/\/doi.org\/10.1111\/1756-185X.13062.","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"2537_CR75","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.chembiol.2018.03.002","volume":"25","author":"R Tilvawala","year":"2018","unstructured":"Tilvawala R, Nguyen SH, Maurais AJ, Nemmara VV, Nagar M, Salinger AJ, et al. The rheumatoid arthritis-associated citrullinome. Cell Chem Biol. 2018;25(6):691\u2013704. e696.","journal-title":"Cell Chem Biol"},{"issue":"11","key":"2537_CR76","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1093\/rheumatology\/keaa125","volume":"59","author":"SH Chu","year":"2020","unstructured":"Chu SH, Cui J, Sparks JA, Lu B, Tedeschi SK, Speyer CB, et al. Circulating plasma metabolites and risk of rheumatoid arthritis in the Nurses\u2019 Health Study. Rheumatology. 2020;59(11):3369\u201379. https:\/\/doi.org\/10.1093\/rheumatology\/keaa125.","journal-title":"Rheumatology"},{"issue":"12","key":"2537_CR77","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1002\/art.39785","volume":"68","author":"EV Marietta","year":"2016","unstructured":"Marietta EV, Murray JA, Luckey DH, Jeraldo PR, Lamba A, Patel R, et al. Suppression of inflammatory arthritis by human gut-derived Prevotella histicola in humanized mice. Arthritis Rheumatol. 2016;68(12):2878\u201388. https:\/\/doi.org\/10.1002\/art.39785.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"2537_CR78","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s00284-013-0338-1","volume":"67","author":"X Liu","year":"2013","unstructured":"Liu X, Zou Q, Zeng B, Fang Y, Wei H. Analysis of fecal Lactobacillus community structure in patients with early rheumatoid arthritis. Curr Microbiol. 2013;67(2):170\u20136. https:\/\/doi.org\/10.1007\/s00284-013-0338-1.","journal-title":"Curr Microbiol"},{"issue":"8","key":"2537_CR79","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/nm.3914","volume":"21","author":"X Zhang","year":"2015","unstructured":"Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D, et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med. 2015;21(8):895\u2013905. https:\/\/doi.org\/10.1038\/nm.3914.","journal-title":"Nat Med"},{"issue":"1","key":"2537_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-016-0009-6","volume":"8","author":"J Sung","year":"2017","unstructured":"Sung J, Kim S, Cabatbat JJT, Jang S, Jin Y-S, Jung GY, et al. Global metabolic interaction network of the human gut microbiota for context-specific community-scale analysis. Nat Commun. 2017;8(1):1\u201312.","journal-title":"Nat Commun"},{"issue":"10","key":"2537_CR81","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41587-019-0233-9","volume":"37","author":"T Wilmanski","year":"2019","unstructured":"Wilmanski T, Rappaport N, Earls JC, Magis AT, Manor O, Lovejoy J, et al. Blood metabolome predicts gut microbiome \u03b1-diversity in humans. Nat Biotechnol. 2019;37(10):1217\u201328. https:\/\/doi.org\/10.1038\/s41587-019-0233-9.","journal-title":"Nat Biotechnol"},{"key":"2537_CR82","doi-asserted-by":"publisher","unstructured":"Gupta VK, Kim M, Bakshi U, Cunningham KY, Davis JM, Lazaridis KN, Nelson H, Chia N, Sung J. A predictive index for health status using species-level gut microbiome profiling. Nat Commun 2020, 11(1):1-16, 4635, doi: https:\/\/doi.org\/10.1038\/s41467-020-18476-8.","DOI":"10.1038\/s41467-020-18476-8"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02537-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02537-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02537-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T01:12:41Z","timestamp":1623114761000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02537-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2537"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02537-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.09.13.20193664","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,8]]},"assertion":[{"value":"16 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Mayo Clinic Institutional Review Board (no. 14-000616 and no. 14-000680) in accordance with the Declaration of Helsinki. All methods and procedures were performed in accordance with the Mayo Clinic Institutional Review Board guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"164"}}